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Neuroferritinopathy is a progressive potentially treatable adult-onsetmovement disorder caused bymutations
in the ferritin light chain gene (FTL1). Features overlap with common extrapyramidal disorders: idiopathic
torsion dystonia, idiopathic Parkinson’s disease andHuntington’s disease, but the phenotype and natural history
have not been defined. We studied a genetically homogeneous group of 41 subjects with the 460InsA mutation
in FTL1, documenting the presentation, clinical course, biochemistry and neuroimaging. Themean age of onset
was 39.4 years (SD = 13.3, range 13–63), beginning with chorea in 50%, focal lower limb dystonia in 42.5% and
parkinsonism in 7.5%. The majority reported a family history of a movement disorder often misdiagnosed as
Huntington’s disease. The disease progressed relentlessly, becoming generalized over a 5–10 year period,
eventually leading to aphonia, dysphagia and severe motor disability with subcortical/frontal cognitive dysfunc-
tion as a late feature. A characteristic action-specific facial dystonia was common (65%), and in 63% there was
asymmetry throughout the disease course. Serum ferritin levels were low in the majority of males and post-
menopausal females, but within normal limits for pre-menopausal females. MR brain imaging was abnormal on
all affected individuals and one presymptomatic carrier. In conclusion, isolated parkinsonism is unusual in
neuroferritinopathy, and unlike Huntington’s disease, cognitive changes are absent or subtle in the early stages.
Depressed serum ferritin is common and provides a useful screening test in routine practice, and gradient echo
brain MRI will identify all symptomatic cases.
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Introduction
Neuroferritinopathy (MIM 606159, also labelled hereditary
ferritinopathy and neurodegeneration with brain iron
accumulation type 2, NBIA2) is an adult-onset progressive
movement disorder due to mutations in the ferritin light
chain gene (FTL1) (Curtis et al., 2001). Four pathogenic
mutations in FTL1 have been described to date (Curtis et al.,
2001; Vidal et al., 2004; Maciel et al., 2005; Mancuso et al.,
2005). 460InsA was the original mutation and has been
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found in the largest number of cases. The resulting altered
reading frame extends the peptide, disrupting the ferritin
dodecahedron structure and causing accumulation of
ferritin and iron, primarily in central neurons (Curtis et al.,
2001; Vidal et al., 2004; Maciel et al., 2005; Mancuso et al.,
2005). The disorder therefore provides a direct link between
disordered iron storage and a neurodegenerative disease,
opening new avenues for treatment by altering brain iron
stores (Crompton et al., 2005).
Based on limited published clinical descriptions,
extrapyramidal neurological features dominate the clinical
presentation of neuroferritinopathy, with focal onset dysto-
nia, chorea and parkinsonism in different family members
(Curtis et al., 2001; Wills et al., 2002; Chinnery et al., 2003;
Vidal et al., 2004; Crompton et al., 2005; Maciel et al., 2005;
Mancuso et al., 2005; Mir et al., 2005). Neuroferritinopathy
thus enters the differential diagnosis of common neurolo-
gical disorders, including idiopathic Parkinson’s disease,
idiopathic torsion dystonia (ITD) and Huntington’s disease.
Given the clinical genetic implications of the diagnosis,
the early diagnosis of neuroferritinopathy is essential with
molecular genetic confirmation. On the other hand, given
the prevalence of Parkinson’s disease and dystonia,
molecular diagnostic services could be overwhelmed with
referrals for FTL1 analysis. There is therefore a clear need to
define the neurological features of neuroferritinopathy in
detail to clarify which patients should have molecular
genetic testing. To address this issue we studied the vast
majority of known cases with the 460InsA FTL1 mutation.
Material and methods
Through clinical or molecular referral to us (J.B./P.F.C.) and by
family tracing 41 subjects were identified.
A total of 105 DNA samples referred to the Northern Genetics
Service with a diagnosis of possible Huntington’s disease, but which
lacked an expansion in theHD gene, were analysed for the 460InsA in
FTL1, leading to the identification of seven further cases. Five of these
were haplotyped and shown to be identical to the Cumbrian pedigree
and therefore presumed to be distant relatives (Chinnery et al., 2003).
The entire FTL1 gene was sequenced in 97 of the HD-negative
patients but nomutations were identified. The samples of 44 patients
referred for dentatorubropallidoluysian atrophy testing but without
an expansion in the DRPLA gene were also analysed specifically for
460InsA. Two had the common mutation, one of them was already
known to be a member of the large pedigree. Media coverage heard
by a colleague in Nottingham identified a further case with a similar
phenotype in the Midlands (Wills et al., 2002), but no further cases
were found in 18 other early referrals. Contact with colleagues in
London, Strasbourg and Leiden identified 144 Huntington-like
cases, which had been found not to have aHD expansion. One of the
119, which could be amplified, a previously identified known case
was positive for the common mutation. The French cases were
identified through personal contact with one of the persons affiliated
with a clinical description of cases in the literature (Caparros-
Lefebvre et al., 1997). The 460InsA insertion was not present in
the 100 anonymized samples from the Cumbrian population
collected as part of a resource for genetic epidemiology.
Of the 41 patients reported here 9 have been described elsewhere
(Caparros-Lefebvre et al., 1997; Wills et al., 2002; Crompton et al.,
2005; Mir et al., 2005). All 41 were studied to define the disease
spectrum, and were assessed clinically by one of us, with 85%
assessed by both P.F.C. and J.B. Examinations included detailed
cognitive assessments (n = 26), serum ferritin (n = 20, multiple
measurements were made in 7), electromyography and nerve
conduction studies (n = 8), brain imaging (29 with MRI, serial in
8, range 5–49 months, and 1 with CT only). Two had dopamine
transporter imaging (DaTSCAN). Nine had a muscle biopsy
analysed histochemically. Six had respiratory chain activities
measured in skeletal muscle (Caparros-Lefebvre et al., 1997;
Taylor and Turnbull, 1997).
Results
Presenting clinical features
Detailed clinical data were available for 21 females and
20 males (Table 1). Case 1 was identified by predictive genetic
testing. There was no significant difference in the mean age of
onset between males and females (two-sample t-test, P = 0.31,
Fig. 1A). Overall, the mean age of onset was 39.4 years (SD =
13.3, range 13–63 years). Of the 40 affected subjects, the
majority presented with focal onset chorea (50%, 20 out of 40)
or focal dystonia (43%, 17 out of 40), which was either in the
leg (76%) or arm (24%). The movements were ballistic in two
individuals, beginning suddenly and leading to a diagnosis of
stroke. One subject described an ‘alien limb’; uncontrolled
semi-purposeful movements in one limb with inter-manual
conflict but no cortical sensory signs. Parkinsonism was the
presenting feature in three individuals (7.5%, 3 out of 40).
Blepharospasm and writer’s cramp were early features in four,
two individuals described marked diurnal variation of their
lower limb dystonia with sleep benefit early in the disease
course, and two had palatal tremor (previously known as
palatal myoclonus). There was no significant gender
difference in the mode of presentation, nor was there a
relationship between the age of onset and the presenting
clinical features.
Clinical course
Follow-up data were available on 38 subjects (range
1–36 years, Table 1, column 3), with patients being assessed
on at least two occasions, the minimum being at
presentation and subsequently on follow-up. The presenting
movement disorder remained the major phenotype, with
clear asymmetry remaining throughout the clinical course in
63%. The vast majority developed dystonia (83%), predo-
minantly in the legs. Likewise, the majority also developed
chorea (70%). Oromandibular dyskinesia was observed in
26 subjects (65%), causing tongue injury in 3; and 25 (63%)
developed a characteristic speech with a dysarthrophonia,
and an action-specific dystonia. This involved symmetric
frontalis and platysma contraction giving a startled appear-
ance. While 35% developed facial hypomimia and bradyki-
nesia not directly related to their dystonia; only one
Neuroferritinopathy Brain (2007), 130, 110–119 111
T
a
b
le
1
C
lin
ic
al
fe
at
u
re
s
o
f
n
eu
ro
fe
rr
it
in
o
p
at
h
y
Ageofonset/duration
offollow-up(years)
P
re
se
n
ti
n
g
p
h
en
o
ty
p
e
Asymmetry
Sp
ee
ch
an
d
sw
al
lo
w
in
g
E
ye
s
M
o
to
r
C
o
gn
it
iv
e*
*
Casenumber/
ethnicorigin
Age(years)/gender
Phenotype
Limb
Dysarthria
Dysphonia
Orolingualdyskinesia
Dysphagia
EOM
Fundi
Bradykinesia
Tremor
Dystonia
Chorea
Spasticity
Power*
Reflexes/Babinski
Ataxia
1
E
4
6
F
N
/A
U
N
A
0
0
0
0
0
N
N
0
0
0
0
0
N
N
/#
0
2
E
4
0
F
4
0
/<
1
D
Le
g
+
0
0
0
0
N
N
0
0
+
0
0
N
N
/#
0
3
E
5
3
M
5
3
/<
1
C
A
rm
0
+
0
+
0
N
N
0
0
+
+
+
+
0
N
N
/#
0
4
E
3
4
F
3
3
/<
1
C
A
rm
0
0
0
+
0
N
N
0
0
+
+
0
N
N
/#
0
5
E
3
9
F
3
8
/<
1
D
A
rm
+
+
+
+
0
+
0
N
N
+
0
+
+
0
0
N
N
/#
0
A
9
4
/1
0
0
#v
er
b
al
flu
en
cy
6
E
3
9
F
3
7
/2
C
A
rm
+
+
+
0
+
+
+
0
N
N
0
0
+
+
+
+
0
N
N
/#
0
7
E
5
3
M
5
1
/2
C
A
rm
+
0
0
0
0
N
N
0
0
0
+
+
+
0
N
N
/#
0
M
3
0
/3
0
A
9
4
/1
0
0
8
E
6
3
F
6
1
/2
C
A
rm
0
+
0
+
+
0
N
N
0
0
+
+
+
+
0
N
N
/#
0
A
7
9
/1
0
0
#v
er
b
al
flu
en
cy
9
E
3
4
M
3
2
/2
D
Le
g
+
0
0
0
+
N
N
0
0
+
+
0
0
N
N
/#
0
N
o
rm
al
p
sy
ch
o
m
et
ry
1
0
E
5
9
M
5
7
/2
C
A
rm
0
+
+
+
+
+
+
+
+
+
+
N
N
+
+
0
+
+
+
+
+
0
N
N
/#
0
A
6
3
/1
0
0
#v
er
b
al
flu
en
cy
1
1
E
5
4
M
5
2
/2
C
A
rm
0
+
+
+
+
+
0
N
N
0
0
0
+
+
0
N
N
/#
0
M
in
o
r
n
o
n
-s
p
ec
ifi
c
d
ef
ic
it
s
1
2
E
4
0
F
3
8
/2
D
Le
g
+
+
+
+
+
+
0
N
N
0
0
+
+
0
0
N
N
/#
0
A
8
4
/1
0
0
#v
er
b
al
flu
en
cy
1
3
Fr
4
8
M
4
4
/4
C
A
rm
+
+
+
+
+
+
0
+
+
+
+
+
+
N
N
+
0
+
+
+
+
0
N
N
/#
0
#V
er
b
al
flu
en
cy
1
4
E
5
8
F
5
3
/5
C
A
rm
0
+
0
+
+
+
0
N
N
0
0
0
+
+
+
0
N
N
/#
0
D
is
in
h
ib
it
ed
1
5
E
3
5
F
3
0
/5
D
Le
g
+
+
+
0
0
N
N
0
0
+
+
0
N
N
/#
0
M
3
0
/3
0
A
9
1
/1
0
0
#
ve
rb
al
flu
en
cy
1
6
E
5
8
M
5
3
/5
C
Le
g
+
+
+
+
+
+
+
+
+
+
+
+
+
N
N
0
0
+
+
+
+
0
N
N
/#
0
N
o
rm
al
p
sy
ch
o
m
et
ry
1
7
E
5
7
M
5
1
/6
C
A
rm
+
+
+
+
+
+
+
+
+
+
+
+
N
N
+
0
+
+
+
+
0
N
N
/#
0
N
o
rm
al
p
sy
ch
o
m
et
ry
1
8
E
3
0
F
2
4
/6
D
A
rm
+
+
+
0
0
0
0
N
N
0
0
+
+
+
0
0
N
+
+
+
/#
0
N
o
rm
al
p
sy
ch
o
m
et
ry
1
9
E
6
0
M
5
4
/6
C
Le
g
+
0
0
0
+
N
N
0
+
0
+
+
+
0
N
N
/#
0
#A
ll
ar
ea
s
2
0
E
6
9
F
6
3
/6
P
G
ai
t
0
+
+
+
0
0
0
N
N
+
+
+
0
+
+
0
0
N
+
+
+
/#
0
2
1
E
5
3
M
4
6
/7
C
Le
g
+
+
+
+
+
+
+
+
+
N
N
+
+
0
+
+
+
+
0
N
+
+
+
/#
0
A
8
7
/1
0
0
#v
er
b
al
flu
en
cy
,
la
b
ile
2
2
E
5
0
F
4
1
/9
C
A
rm
0
+
+
+
0
+
+
+
0
N
N
0
0
+
+
+
+
0
N
N
/#
0
N
o
rm
al
p
sy
ch
o
m
et
ry
2
3
E
4
4
M
3
5
/9
D
A
rm
+
+
+
+
+
+
+
+
+
0
N
N
+
0
+
+
+
+
0
N
+
+
+
/#
0
D
is
in
h
ib
it
ed
2
4
E
6
5
F
5
5
/1
0
P
A
rm
0
+
0
+
+
0
N
N
+
+
0
0
0
0
N
N
/#
0
2
5
E
5
3
F
4
2
/1
1
D
Le
g
+
+
+
+
+
+
+
+
+
+
+
+
+
+
N
N
+
0
+
+
+
+
0
N
+
+
+
/#
0
G
lo
b
al
co
gn
it
iv
e
d
ec
lin
e
2
6
E
4
9
M
3
7
/1
2
C
Sp
ch
0
+
+
+
0
+
+
+
0
B
P
N
0
0
+
+
+
+
+
+
0
N
N
/#
0
Fr
o
n
ta
l/
su
b
co
rt
ic
al
d
ef
ic
it
2
7
E
3
8
F
2
3
/1
5
D
Le
g
+
+
+
+
+
+
+
+
+
0
+
+
+
N
N
+
+
+
0
+
+
+
+
0
N
+
+
+
/#
0
2
8
E
6
2
F
4
7
/1
5
D
Le
g
+
+
+
+
+
+
+
+
+
0
+
+
+
N
N
0
0
+
+
+
0
0
N
N
/#
0
M
ild
#n
ew
le
ar
n
in
g
&
re
as
o
n
in
g
112 Brain (2007), 130, 110–119 P. F. Chinnery et al.
T
a
b
le
1
C
on
tin
ue
d Ageofonset/duration
offollow-up(years)
P
re
se
n
ti
n
g
p
h
en
o
ty
p
e
Asymmetry
Sp
ee
ch
an
d
sw
al
lo
w
in
g
E
ye
s
M
o
to
r
C
o
gn
it
iv
e*
*
Casenumber/
ethnicorigin
Age(years)/gender
Phenotype
Limb
Dysarthria
Dysphonia
Orolingualdyskinesia
Dysphagia
EOM
Fundi
Bradykinesia
Tremor
Dystonia
Chorea
Spasticity
Power*
Reflexes/Babinski
Ataxia
2
9
E
7
6
F
5
9
/1
7
D
A
rm
+
+
0
0
0
0
N
N
+
+
+
+
+
0
0
N
N
/#
0
3
0
E
5
2
M
3
5
/1
7
D
Le
g
+
+
+
+
+
+
+
+
+
+
+
+
N
N
+
+
0
+
+
+
+
+
0
N
N
/"
0
3
1
E
5
9
F
4
2
/1
7
P
Sp
ch
0
+
+
+
0
+
+
+
0
B
P
N
0
0
+
+
+
+
0
N
N
/#
0
3
2
E
6
2
F
4
5
/1
7
C
A
rm
0
+
+
+
+
+
+
+
0
#U
G
N
0
0
+
+
+
+
+
+
0
N
N
/#
0
3
3
E
4
0
M
2
2
/1
8
D
Le
g
0
+
+
+
+
+
+
+
+
+
+
+
+
N
N
0
0
+
+
+
0
0
N
N
/#
0
N
o
rm
al
p
sy
ch
o
m
et
ry
3
4
E
5
4
F
3
3
/2
1
D
Le
g
+
+
+
+
+
+
+
+
+
+
+
+
+
N
N
0
0
+
+
+
+
0
N
N
/#
0
3
5
E
5
0
M
2
5
/2
5
C
A
rm
+
+
+
+
+
+
+
+
+
0
N
N
+
0
+
+
+
+
+
+
0
N
+
+
+
/#
0
#V
er
b
al
flu
en
cy
3
6
Fr
5
3
M
2
4
/2
9
D
Le
g
+
+
+
+
+
+
+
+
+
0
+
+
+
N
N
0
0
+
+
+
0
0
N
N
/#
0
M
2
8
/3
0
#v
er
b
al
flu
en
cy
3
7
E
4
4
F
1
3
/3
1
C
A
rm
0
+
0
+
0
N
N
0
0
+
+
+
+
0
N
N
/#
0
A
8
0
/7
0
#v
er
b
al
flu
en
cy
3
8
E
4
9
M
1
7
/3
2
C
A
rm
+
+
+
0
0
0
0
N
N
0
0
0
+
+
+
0
N
N
/#
0
3
9
Fr
6
0
M
2
7
/3
3
D
Le
g
0
+
+
+
+
+
+
0
+
+
+
N
N
+
+
0
+
+
+
0
0
N
N
/#
0
Li
m
it
ed
b
y
ap
h
o
n
ia
4
0
E
5
1
M
1
7
/3
4
C
A
rm
+
+
+
0
0
0
0
N
N
0
0
0
+
+
+
0
N
N
/#
0
4
1
E
6
1
M
2
5
/3
6
D
Le
g
+
+
+
+
+
+
+
+
+
N
N
0
0
+
+
+
+
0
N
N
/#
0
N
o
rm
al
p
sy
ch
o
m
et
ry
C
as
es
o
rd
er
ed
b
as
ed
o
n
d
u
ra
ti
o
n
si
n
ce
th
e
o
n
se
t
o
f
sy
m
p
to
m
s,
w
it
h
as
ym
p
to
m
at
ic
an
d
re
ce
n
t
o
n
se
t
ca
se
s
at
th
e
to
p
.
E
th
n
ic
o
ri
gi
n
:
E
=
E
n
gl
is
h
.
Fr
=
Fr
en
ch
.
P
h
en
o
ty
p
e:
U
=
u
n
af
fe
ct
ed
;
C
=
ch
o
re
a;
D
=
d
ys
to
n
ia
;
P
=
p
ar
ki
n
so
n
is
m
.
*P
o
w
er
in
n
o
n
-d
ys
to
n
ic
lim
b
s.
**
M
=
M
M
SE
,
A
=
A
d
d
en
b
ro
o
ke
s
co
gn
it
iv
e
sc
o
re
,
E
O
M
=
ex
te
rn
al
o
cu
la
r
m
o
ve
m
en
ts
.
N
/A
n
o
t
ap
p
lic
ab
le
,
Sp
ch
=
sp
ee
ch
,
#U
G
=
lim
it
ed
u
p
-g
az
e.
B
P
=
b
ro
ke
n
o
cu
la
r
p
u
rs
u
it
m
o
ve
m
en
ts
.
G
lo
b
al
co
gn
it
iv
e
d
ec
lin
e
=
co
gn
it
iv
e
d
ef
ic
it
s
in
al
l
m
o
d
al
it
ie
s
p
re
se
n
t.
Neuroferritinopathy Brain (2007), 130, 110–119 113
individual developed a pure rest tremor, and another had
tremor present at rest and on intention. The majority of
subjects remained ambulant two decades after onset.
The most severe physical disability was seen in subjects
presenting with a predominantly dystonic phenotype.
Although dysphagia was common (40%), this could be
effectively managed with dietary advice in most cases.
Severe dystonic hypophonia and aphonia required speech
amplification in four individuals.
Consistent negative/normal findings included: fundoscopy
(n = 38), slit-lamp examination (n = 8); well preserved
eye movements, with broken ocular pursuit in two (5%)
and non-correcting limitation of up-gaze in one (3%). Brisk
tendon reflexes were uncommon (13% in upper limbs,
18% in lower limbs), and none developed overt spasticity.
Extensor plantar responses were noted in one individual
(3%) which were probably striatal toes given the leg
dystonia and normal tendon reflexes. None had documented
seizures.
Cognitive features were subtle early in the disease course.
The majority (56%, 5 out of 9) of subjects whose symptoms
began <10 years previously had normal psychometric
profiles, with the remaining 44% (4 out of 9) showing
mild defects of verbal fluency. The remaining 44% (4 out of
9) had normal psychometry >10 years after symptom onset,
among whom 33% (3 out of 9) had mild abnormalities
of verbal fluency at >10 years of onset, and two had features
consistent with a frontal/subcortical dementia (present
12 and 29 years after onset). One subject (Case 41) had a
normal psychometric profile 36 years after onset. Disinhibi-
tion and emotional lability were frequently noted even in the
early stages. One individual presented with a paranoid
psychosis. Mini-Mental State Examination was not sensitive
for the frontal/subcortical cognitive deficits.
Clinical investigations
Full blood count and film, urea and electrolytes, liver and
bone biochemistry, plasma glucose, HbA1c, and serum
creatine kinase were normal (n = 11). CSF analysis was
normal (n = 6) with the exception of an elevated CSF
protein (0.8 g/l) in one subject (Case 10). Fasting plasma
and CSF lactate were normal (Cases 14, 23, 28 and 30).
Serum ferritin levels were below the normal range for iron
deficiency, despite normal haemoglobin and serum iron
levels (Fig. 1B) in 82% of males (9 out of 11) and all
post-menopausal females (3 out of 3) but only 23% of pre-
menopausal females (3 out of 13). In seven subjects there
were serial ferritin measurements, with values remaining
below the reference range. There was no relationship
between age or disease duration and the serum ferritin.
Electroretinography (n = 3), electromyography (n = 8)
and peripheral nerve conduction studies (n = 8) were
normal. Electroencephalography (n = 11) was normal
apart from minor non-specific slowing of the alpha rhythm
in two.
None of the subjects reported or were shown to have
symptomatic disease in other organs. One subject required
an implanted cardiac pacemaker.
Muscle biopsy
Nine subjects had a muscle biopsy prior to diagnosis.
Histochemistry was normal in seven. Two had a greater
percentage of cytochrome c oxidase negative fibres than
expected for age (2% in a 48-year-old, Case 25; and 1% in a
45-year-old, Case 37). Respiratory chain complex assays
were performed in six subjects [three of these results were
published before reaching the molecular diagnosis
(Caparros-Lefebvre et al., 1997)]. Two had a combined
defect involving multiple respiratory chain complexes
(I and III, Case 13; I, III and IV, Case 36), and three had
an isolated defect involving complex I (Cases 21, 37 and 39).
In one subject (Case 25), respiratory chain complex
activities were normal in muscle and cultured skin
fibroblasts.
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Fig. 1 (A) Age of onset for 40 affected individuals with
neuroferritinopathy. Mean age of onset for females = 41.4 years
(SD = 13.1). Mean age of onset for males was 37.1 years
(SD = 13.6). There was no significant difference between males and
females (two-sample t-test, P = 0.31). (B) Serum ferritin levels
for 20 subjects with neuroferritinopathy. Black squares = males,
red circles = pre-menopausal females, green triangles = post-
menopausal females. Seven subjects had serial measurements
over time (difference between the two measurements,
mean = 13 months, range 4–25 months). Note that two
pre-menopausal women had a ferritin measurement of 12 mg/l
when presenting with symptoms for the first time, leading to
two superimposed data points. Haemoglobin levels were normal
at the time of all ferritin measurements. Horizontal lines show
the lower limit of normal for males, post-menopausal females,
and pre-menopausal females.
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Brain MR imaging
A characteristic pattern of signal change was observed in all
subjects, consistent with iron deposition predominantly in
the basal ganglia (Fig. 2). Serial scans of the same subject
performed up to 49 months apart did not demonstrate
significant qualitative change.
Even in an asymptomatic carrier, a characteristic
pattern of iron deposition was seen on gradient echo
sequences, consisting of loss of T2* signal within the dentate
nuclei, red nuclei, substantia nigra, putamina, globi pallidi,
thalami, caudate nuclei and the Rolandic prefrontal cortex.
In early cases, the only discernible abnormality on
Fig. 2 Brain magnetic resonance imaging in neuroferritinopathy. Left hand images: asymptomatic subject (Case 1, who had predictive testing
and harboured the 460InsA FTL1 mutation). Profound signal loss is noted on T2* imaging in red nuclei, substantia nigra and globus pallidus,
with less marked loss in dentate nuclei, thalami, putamen, caudate nucleus head, and precentral gyrus. Abnormalities are inconspicuous on
T2, except for minor low signal in red nuclei and substantia nigra. Middle images: intermediate case (Case 12). T2* signal loss is present in the
same locations, but also within the internal capsules, and more prominently within the dentate nuclei and thalami. T2 now shows signal
abnormality in the lentiform and caudate nuclei, particularly focally in the globus pallidus and posterior putamen, mirroring areas of high
signal on T1 (indicative of mineral deposition). Right hand images: advanced case (Case 35). The pallidal lesions have now undergone internal
cystic degeneration. There is involutional change, and there are several small vessel ischaemic lesions present.
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conventional spin echo MR sequences in this group was a
mild reduction in T2 signal within the red nuclei and
substantia nigra.
In increasingly severe disease, T2* signal loss became more
pronounced within the dentate nuclei, thalami and globi
pallidi, with abnormal T2 signal in the lentiform and caudate
nuclei, mirroring areas of high signal on T1 in these locations,
and indicating mineral deposition. As the disease advanced
there was more pronounced focal signal abnormality within
the globus pallidus, with central high T2 and FLAIR signal and
peripheral high T1, consistent with focal pre-cystic degenera-
tion. In advanced cases, these foci showed internal cystic
degeneration associated with generalized involutional changes
and an excess of small vessel ischaemic lesions.
T1 weighted images from the same subjects are shown
in Fig. 3, demonstrating the sensitivity of T2* imaging,
particularly in early disease. The MR findings were the same
in the two patients with palatal tremor.
DaTScan imaging
There was no evidence of a presynaptic nigrostriatal
dopaminergic deficit in two symptomatic subjects (Cases 5
and 9, Fig. 4).
Discussion
We have defined the phenotype of neuroferritinopathy.
Our early suspicion of earlier male clinical onset is not
confirmed; there is no gender difference in the age of onset,
features or progression. With one exception, all of the
individuals tested for the disorder had clinical features of the
disease. We have not formally studied penetrance by
systematically carrying out genetic testing in unaffected
individuals, but re-analysis of the linkage data in our
original paper (Curtis et al., 2001) indicates a very high life-
time penetrance for the 460InsA FTL1 mutation, in the
order of 100%.
To date, four different pathogenic mutations of FTL1 have
been identified, all affecting exon 4 (Curtis et al., 2001;
Maciel et al., 2005; Mancuso et al., 2005; Vidal et al., 2004).
A male with a 2 bp insertion in exon 4 of FTL1 (498InsTC)
presented aged 20 with tremor followed by cerebellar signs
aged 47 (dysarthria and ataxia, but no nystagmus), frontal/
sub-cortical cognitive impairment, dyskinesia (described
as involuntary movement of the face, resembling tardive
dyskinesia, evolving into dystonic posturing and buccolin-
gual dyskinesia), brisk tendon reflexes and Babinski signs
(Vidal et al., 2004). The 646InsC mutation was identified in
a 63-year-old man presenting with chorea, limb ataxia,
areflexia and bilateral extensor plantar responses (Mancuso
et al., 2005). The 474G!A (A96T) mutation was found in a
man with mild non-progressive mental retardation, who
developed a gait disturbance at 13 years of age, followed by
episodes of psychosis treated with neuroleptics. He
subsequently developed an akinetic-rigid syndrome, ataxia
and pyramidal signs. His 40-year-old mother also harboured
the same mis-sense mutation and was asymptomatic (Maciel
et al., 2005). With the exception of the reported cerebellar
signs, the clinical presentation of the patients with the
498InsTC and 646InsC mutations fall within the spectrum
we have seen in patients with 460InsA. The facial and
orolingual dyskinesia appears to be a consistent finding, and
is characteristic of neuroferritinopathy. It is intriguing that
all three mutations alter the reading frame, leading to a
lengthening of the C-terminus of FTL. By contrast, the
clinical picture was strikingly different in the patient with a
mis-sense mutation. It is tempting to suggest that mis-sense
mutations cause a different phenotype, although neuroleptic
medication may have complicated the picture. Prominent
psychiatric features were noted in one case with 460InsA
(Wills et al., 2002). Despite the clinical differences, the
neuroimaging was similar in cases with all four FTL1
mutations.
The overwhelming majority of individuals have a relevant
family history but this was often overlooked due to variable
diagnostic labels. Historically, many affected relatives were
admitted to psychiatric institutions for many decades before
death. These relatives were not included in this study, but
case review revealed the reason for admission was not
Fig. 3 Brain magnetic resonance imaging in neuroferritinopathy. T1 weighted images acquired on the same subjects as shown in Fig. 2. Left
hand panel: faint increase in T1 signal in the putamen bilaterally in the asymptomatic case (Case 1). Middle panel: more prominent signal
increase in the periphery of the putamen and globus pallidus in the intermediate case (Case 12). Right hand panel: prominent peripheral signal
increase surrounding the cystic degeneration of the putamen and globus pallidus in the advanced case (Case 35).
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psychiatric disturbance per se, but abnormal involuntary
movements considered psychogenic.
The original family carried a clinical diagnosis of
Huntington’s disease, but the lack of cognitive impairment
over many years of follow-up first alerted us to this new
disease. Only 50% of individuals had demonstrable
cognitive deficits ten years after disease onset. This contrasts
with Huntington’s disease, where memory, attention and
concentration are affected early in the disease (Massman
et al., 1990; Pillon et al., 1991). Even in advanced
neuroferritinopathy, the deficit was subtle, usually involving
verbal fluency. Only two individuals developed a clear
frontal/subcortical dementia, and intriguingly, there was not
an obvious relationship between the severity of the cognitive
phenotype and disease duration. It is therefore likely that
other factors modulate phenotype.
Neuroferritinopathy shares features with other inherited
movement disorders. A dominant family history of a
movement disorder raises the possibility of Huntington’s
disease and Huntington-like disease (Margolis et al., 2001),
idiopathic torsion dystonia (Bressman et al., 2000) or
spinocerebellar ataxia [particularly SCA17 (Nakamura et al.,
2001)]. The well-preserved cognition makes Huntington’s
disease unlikely, and the absence of ataxia, as in the majority
of patients with neuroferritinopathy, would be unusual
for SCA17 (Rolfs et al., 2003; Craig et al., 2005). Two
individuals presenting with focal lower-limb dystonia with
secondary generalization were thought to have DYT1
idiopathic torsion dystonia until exclusion of the Torsin A
CAG deletion (Bressman et al., 2000). Neuroferritinopathy is
distinguished from autosomal dominant dopa-responsive
dystonia due to mutations in GCH1 (Tassin et al., 2000) and
Parkin mutation positive Parkinson’s disease (Lucking et al.,
2000) by unresponsiveness to L-dopa.
A number of non-dominant neurogenetic disorders
also enter the differential diagnosis of neuroferritinopathy,
including Nieman–Pick disease type C (NPC) (Fink et al.,
1989), X-linked (McLeod’s) neuroacanthocytosis (mutations
in XK) (Ho et al., 1994), and recessive choreoacanthocytosis
(mutations in VPS13A)(Rampoldi et al., 2001), pantothenate
kinase (PANK) deficiency (previously known as
Hallervorden–Spatz disease, mutations in PANK2; Hayflick
et al., 2003), and mitochondrial disease (Hanna and Bhatia,
1997). Normal eye movements make NPC unlikely and a
normal creatine kinase, the absence of a compensated
haemolysis, normal nerve conduction studies and the
Fig. 4 18F-dopa PET scan in an early case of neuroferritinopathy (images from Case 9, corresponding to the early case in Fig. 2). No evidence
of a nigrostriatal dopaminergic deficiency.
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absence of seizures reduce the likelihood of McLeod’s disease
and recessive choreoacanthocytosis.
There are neuroradiological similarities between neuro-
ferritinopathy and PANK2 deficiency (Hayflick et al., 2003),
recessive aceruloplasminaemia (mutations CP)(Grisoli et al.,
2005), and mitochondrial disorders (Barragan-Campos et al.,
2005). Aceruloplasminaemia can present with psychiatric
features in late middle age, but is usually preceded by
anaemia with diabetes mellitus and retinal degeneration in
association with a low serum caeruloplasmin and a high
ferritin (Morita et al., 1995). The slowly progressive form of
PANK2 deficiency presents in the second or third decade
with a speech disturbance, psychiatric features and an
extrapyramidal disturbance (Hayflick et al., 2003). Spasticity
is a major feature, although this can be difficult to
distinguish from dystonia, and the retinopathy and optic
atrophy seen in the early-onset forms are uncommon when
the disorder presents later in life. In males and non-
menstruating females, the serum ferritin will help to
distinguish PANK2 deficiency from neuroferritinopathy—
but mutation analysis may be required to make a definitive
diagnosis, particularly in pre-menopausal women.
The clinical and radiological overlap with mitochondrial
disorders is intriguing, particularly given the respiratory
chain defects noted in skeletal muscle in five of the six
460InsA cases studied here, and possibly in the cerebellum
of one other case [646InsC (Mancuso et al., 2005)].
Additional brain immunocytochemical abnormalities point
to a secondary defect of the respiratory chain in
neuroferritinopathy (Mancuso et al., 2005), which, given
the clinical similarity to primary mitochondrial disorders
(McFarland et al., 2002), could be a key mechanism
initiating neurodegeneration in the basal ganglia. Abnormal
iron storage and respiratory chain defects have been
implicated in a number of more common neurodegenerative
movement disorders, including Parkinson’s disease
(Jellinger, 1999), adding weight to the view that under-
standing rare metabolic disorders has broader relevance.
The most difficulty arises from the common movement
disorders seen in some neuroferritinopathy patients early in
the disease course, such as writer’s cramp (n = 1),
blepharospasm (n = 2), restless legs (n = 2) and
parkinsonism. Although a family history is helpful, the
presentation of neuroferritinopathy in middle age means
that this is not always reliable, with parents occasionally
dying from another illness before developing features of
the disorder. Although a serum ferritin level may help, this
can be normal, and brain MR imaging or molecular genetic
analysis are the only ways of providing a definitive answer.
Such detailed investigation is unnecessary in the vast
majority of patients with non-familial focal movement
disorders. However, if there is clinical progression, a strong
family history, or an inappropriately low serum ferritin, we
recommend MR T2* imaging in the first instance, and
molecular genetic testing if there is clear evidence of
abnormal iron storage in the basal ganglia.
The heterogeneous clinical presentation and lack of
natural history data make it difficult to assess the outcome
of treatments, and our observations can only be considered
largely anecdotal, albeit from a large group of patients
by a limited number of clinicians. We have seen both
subjective and objective improvements in the hyperkinetic
movements with sulpiride (n = 3, max. dose 400 mg daily)
and tetrabenazine (n = 11, max. dose 125 mg), although
three had to stop the latter drug because they developed
depression. Three subjects reported an improvement with
trihexyphenidyl (benzhexol, max. dose 16 mg), L-dopa had
no effect in five (max dose 375 mg daily), and deanol (20 mg
t.i.d) was ineffective in two. Baclofen (n = 2, max dose 60 mg
daily) and dantrolene (n = 2, max. dose 400 mg daily)
were also tried without convincing benefit. Diazepam
(20 mg daily), clonazepam (1 mg daily) and lorazepam
(max. dose 15 mg daily) subjectively improved the dystonia,
each in two patients. Other agents that did not have an effect
on the movement disorder were: apomorphine (n = 1),
amantadine (n = 1), lorazepam (n = 2), olanzapine (n = 1),
risperidone (n = 1), amitriptyline (n = 2), paroxetine (n = 1),
mirtazapine (n = 1), gabapentin (n = 1), sodium valproate (n
= 1), and carbamazapine (n = 1), all in standard doses.
Botulinum toxin has helped the focal dystonia (n = 4) and
hyperkinetic tongue in two subjects.
We have tried to reduce brain iron stores in three subjects,
documenting the clinical course with a videoed standardized
examination. Three had monthly venesection for 6 months,
and two had intravenous desferrioxamine (4000 mg weekly
subcutaneously for up to 14 months), and one had oral
deferriprone (2 g t.i.d for 2 month). All three measures caused
profound and refractory iron depletion. One individual with
generalized dystonia deteriorated significantly during the
treatment period, and the other subjects did not notice any
benefit.We conclude that a short period of iron depletion does
not have a dramatic affect in the short term, but longer term
benefits remain a possibility.
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